《大行》瑞銀首予三生製藥(01530.HK)「買入」評級 目標價30元 重大許可協議印證研發能力
瑞銀髮表報告,首次覆蓋三生製藥(01530.HK),給予「買入」評級,目標價30元。
報告指,三生製藥核心產品針對血液學和自身免疫疾病,認爲,近期與輝瑞(PFE.US)就SSGJ-707(PD-1/VEGF雙特異性抗體)達成的總額創紀錄61.5億美元的許可協議,體現了對三生強大研發能力的認可。
該行看好SSGJ-707海外高峯銷售額及其他管線資產價值的上升潛力,預測三生製藥在2024至2034年間的收入和淨利潤年均複合增長率分別爲11.7%和12.1%。關鍵催化劑包括2025年下半年SSGJ-707數據更新的潛在可能性;第三季度預付款收入入賬;SSGJ-707海外臨牀試驗的啓動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.